Sökning: WFRF:(Solberg A. O.) >
One course of adjuv...
One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group
-
- Tandstad, T. (författare)
- St Olavs University Hospital, Norway
-
- Ståhl, Olof (författare)
- Lund University,Lunds universitet,Reproduktionsmedicin, Malmö,Forskargrupper vid Lunds universitet,Reproductive medicine, Malmö,Lund University Research Groups,Skåne University Hospital, Sweden
-
- Håkansson, Ulf (författare)
- Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine,Skåne University Hospital, Sweden
-
visa fler...
-
- Dahl, O. (författare)
- University of Bergen, Norway; Haukeland Hospital, Norway
-
- Haugnes, H. S. (författare)
- University of Tromso, Norway; University Hospital North Norway, Norway
-
- Klepp, O. H. (författare)
- Alesund Hospital, Norway
-
- Langberg, C. W. (författare)
- Oslo University Hospital, Norway
-
- Laurell, Anna (författare)
- Uppsala universitet,Enheten för onkologi,University of Uppsala Hospital, Sweden
-
- Oldenburg, J. (författare)
- Oslo University Hospital, Norway
-
- Solberg, A. (författare)
- St Olavs University Hospital, Norway
-
- Söderström, Karin (författare)
- The Cancer Clinic, Norrland University Hospital, Umeå,Norrland University Hospital, Sweden
-
- Cavallin-Ståhl, Eva (författare)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital, Sweden
-
- Stierner, U. (författare)
- Sahlgrens University Hospital, Sweden
-
- Wahlquist, R. (författare)
- Oslo University Hospital, Norway
-
- Wall, Najme (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet,Onkologiska kliniken US
-
- Cohn-Cedermark, G. (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2014
- 2014
- Engelska.
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 25:11, s. 2167-2172
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
http://www.ncbi.nlm....
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://urn.kb.se/re...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- The SWENOTECA group treated 517 clinical stage I nonseminoma patients with one course of adjuvant BEP in a prospective study. The median follow-up is 7.9 years. One course of adjuvant BEP reduced the risk of relapse by over 90%. The relapse rates were 1.6% in low-risk disease and 3.2% in high-risk disease. One course of adjuvant BEP should be considered a standard adjuvant treatment option.SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results. In a prospective, binational, population-based risk-adapted treatment protocol, 517 Norwegian and Swedish patients with CS I nonseminoma received one course of adjuvant BEP. Patients with lymphovascular invasion (LVI) in the primary testicular tumor were recommended one course of adjuvant BEP. Patients without LVI could choose between surveillance and one course of adjuvant BEP. Data for patients receiving one course of BEP are presented in this study. At a median follow-up of 7.9 years, 12 relapses have occurred, all with IGCCC good prognosis. The latest relapse occurred 3.3 years after adjuvant treatment. The relapse rate at 5 years was 3.2% for patients with LVI and 1.6% for patients without LVI. Five-year cause-specific survival was 100%. The updated and expanded results confirm a low relapse rate following one course of adjuvant BEP in CS I nonseminoma. One course of adjuvant BEP should be considered a standard treatment in CS I nonseminoma with LVI. For patients with CS I nonseminoma without LVI, one course of adjuvant BEP is also a treatment option.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- testicular cancer
- adjuvant chemotherapy
- nonseminoma
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Tandstad, T.
-
Ståhl, Olof
-
Håkansson, Ulf
-
Dahl, O.
-
Haugnes, H. S.
-
Klepp, O. H.
-
visa fler...
-
Langberg, C. W.
-
Laurell, Anna
-
Oldenburg, J.
-
Solberg, A.
-
Söderström, Kari ...
-
Cavallin-Ståhl, ...
-
Stierner, U.
-
Wahlquist, R.
-
Wall, Najme
-
Cohn-Cedermark, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Umeå universitet
-
Lunds universitet
-
Uppsala universitet
-
Linköpings universitet
-
Karolinska Institutet